Daily Cardiology Research Analysis
Analyzed 253 papers and selected 3 impactful papers.
Summary
Three studies stand out today: a translational large-animal investigation demonstrating intrapericardial delivery of a stromal cell secretome–loaded hydrogel improves post–myocardial infarction repair; a real-world AI echocardiography system that accurately detects mitral valve prolapse and clinically significant regurgitation with external validation; and a comprehensive meta-analysis with trial sequential analysis showing remote patient monitoring reduces mortality and heart failure hospitalizations.
Research Themes
- Translational regenerative cardiology using acellular secretome delivery
- Clinical deployment of AI in echocardiography for valvular heart disease
- Remote patient monitoring reducing mortality in heart failure
Selected Articles
1. Intrapericardially injected hydrogel loaded with stromal cell secretome microparticles improves post-infarction myocardial repair in pigs.
In a porcine myocardial infarction model, intrapericardial delivery of a hyaluronic acid hydrogel embedding stromal cell secretome microparticles (RESCAT) improved cardiac function, reduced infarct size, and increased cardiomyocyte cell-cycle activity. Single-nucleus RNA sequencing linked an FN1+ cardiomyocyte state with PI3K–Akt activation, suggesting engagement of survival and growth pathways.
Impact: This study demonstrates a minimally invasive, acellular, off‑the‑shelf regenerative strategy with mechanistic resolution in a large-animal model—key steps toward clinical translation for post-MI repair.
Clinical Implications: While preclinical, intrapericardial acellular therapy could complement or replace cell-based approaches, enabling catheter-based delivery to enhance endogenous repair post-MI. It supports future first-in-human feasibility trials.
Key Findings
- RESCAT improved cardiac function and reduced infarct size versus controls in pigs.
- Cardiomyocyte cell-cycle activity was enhanced after RESCAT treatment.
- Single-nucleus RNA-seq identified an FN1+ cardiomyocyte subtype associated with PI3K–Akt pathway activation.
Methodological Strengths
- Clinically relevant large-animal (porcine) MI model with intrapericardial delivery.
- Multimodal endpoints including longitudinal function, histology, and single-nucleus transcriptomics.
Limitations
- Sample size and detailed safety/tolerability metrics are not reported in the abstract.
- Translational uncertainty remains regarding durability and dosing in humans.
Future Directions: Design first-in-human feasibility studies assessing safety, dosing, delivery logistics, and early efficacy; refine hydrogel formulation and secretome composition; evaluate synergy with guideline-directed post-MI therapies.
BACKGROUND AND AIMS: Myocardial infarction (MI) stands as a prominent manifestation of cardiovascular events. Most of the regenerative effects of stem cell therapies for MI are paracrine. A clinically translatable strategy that harnesses regenerative secretome while enabling minimally invasive delivery is needed. This study evaluated Regenerative Encapsulated Secretome as Cardiac Acellular Therapy (RESCAT), a formulation composed of cardiac stromal cell-derived secretome encapsulated in microparticles and embedded within a hyaluronic acid hydrogel, delivered via intrapericardial injection in a porcine model of MI. METHODS: MI was induced using minimally invasive techniques. RESCAT was administered through clinically feasible intrapericardial delivery. Cardiac structure and function were assessed longitudinally in vivo. After the endpoint, infarct size and cardiomyocyte cell-cycle activity were assessed with histology. Single-nucleus RNA sequencing was performed to characterize cardiomyocyte transcriptional states and identify molecular pathways associated with therapeutic response. RESULTS: RESCAT-treated pigs showed improved cardiac function and reduced infarct size compared with control groups. Enhanced cardiomyocyte cell-cycle activity and alterations in cardiomyocyte functional state were also observed. Single-nucleus transcriptomic analysis identified an FN1-expressing cardiomyocyte subtype linked to the activation of the PI3K-Akt pathway, which plays a role in cell survival and growth. CONCLUSIONS: Intrapericardial delivery of RESCAT promotes functional and structural cardiac recovery in a clinically relevant porcine MI model. These findings support a minimally invasive, off-the-shelf acellular therapeutic strategy that enhances endogenous repair mechanisms and provides a foundation for translational development in ischaemic heart disease.
2. Automated echocardiographic detection of mitral valve prolapse and mitral regurgitation with video-based artificial intelligence algorithms.
Using 24,869 and 27,906-study training cohorts, multi-view deep neural networks accurately detected mitral valve prolapse (AUC 0.917; external 0.835) and moderate-to-severe mitral regurgitation in MVP patients (AUC 0.877). Performance was strongest in high-risk phenotypes (mitral annular disjunction, bileaflet MVP).
Impact: Demonstrates externally validated, scalable AI for automated MVP/MR assessment across standard echo views, addressing operator variability and enabling rapid, system-wide screening and triage.
Clinical Implications: Can standardize MVP/MR detection, prioritize advanced imaging or referrals, and support longitudinal surveillance, particularly for phenotypes at higher arrhythmic or degenerative risk.
Key Findings
- MVP detection achieved AUC 0.917 internally and 0.835 in external validation.
- Moderate-to-severe MR in MVP patients was detected with AUC 0.877.
- Performance was higher in phenotypes with mitral annular disjunction or bileaflet MVP.
Methodological Strengths
- Very large multi-view video datasets and clear phenotype-specific performance reporting.
- External validation in a demographically distinct cohort.
Limitations
- Retrospective design; model performance in community labs and handheld devices not yet shown.
- Explainability and calibration across vendors and machines require further study.
Future Directions: Prospective, multi-center clinical impact studies, integration into workflow with decision support, and evaluation on handheld/point-of-care ultrasound and diverse vendors.
AIMS: We aimed to develop and evaluate fully automated artificial intelligence (AI) system for detection of mitral valve prolapse (MVP) and mitral regurgitation (MR) from echocardiographic studies. METHODS AND RESULTS: We used a dataset of 24 869 echocardiographic studies from the University of California San Francisco (UCSF) to train a multi-view deep neural network (DNN) to detect MVP using apical four-chamber, two-chamber, and parasternal long-axis views. A separate dataset of 27 906 studies from UCSF was used to train a second multi-view DNN model to detect moderate-to-severe or severe MR using colour Doppler in the same views. External validation was performed on echocardiographic MVP videos from Houston Methodist Hospital. The DNN model for MVP detection achieved an area under the receiver operating characteristic curve (AUC) of 0.917 [95% confidence interval (CI): 0.899-0.934], with stronger performance in those with mitral annular disjunction (MAD) or bileaflet MVP. External validation for MVP detection in a geographically and demographically distinct population yielded an AUC of 0.835 (95% CI: 0.803-0.869). The DNN for detection of moderate-to-severe or severe MR in patients with concurrent MVP achieved an AUC of 0.877 (95% CI: 0.805-0.939). CONCLUSION: Artificial intelligence algorithms can perform automatic detection of MVP and clinically significant MR from echocardiogram studies with high performance. The MVP DNN performed particularly well for more severe MVP phenotypes such as MAD or bileaflet MVP. These algorithms could provide a novel approach for automated, accurate, and rapid diagnosis of MVP and its common clinical sequelae across institutions.
3. Remote Patient Monitoring in Heart Failure: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
Across 59 poolable RCTs (~23,000 participants), remote patient monitoring reduced all-cause mortality (RR 0.911) with trial sequential analysis supporting a stable mortality benefit, and reduced heart failure hospitalizations (RR 0.781). Effects were consistent across structured telephone support, non-invasive telemonitoring, and invasive hemodynamic monitoring.
Impact: Provides contemporary synthesis with trial sequential analysis and GRADE showing mortality reduction from RPM in HF, informing guideline and payer decisions on remote care investments.
Clinical Implications: Supports implementation of RPM programs across modalities to reduce mortality and HF admissions; highlights the need to monitor program design, local contexts, and equity to optimize benefits.
Key Findings
- All-cause mortality reduced with RPM (RR 0.911; TSA indicated sufficient information size).
- Heart failure hospitalizations reduced (RR 0.781), while all-cause hospitalizations were not significantly changed.
- No significant effect modification by RPM modality; GRADE certainty moderate for mortality, low for HF hospitalization.
Methodological Strengths
- Use of REML with Hartung–Knapp–Sidik–Jonkman adjustment and trial sequential analysis.
- GRADE certainty assessment and broad modality coverage across 59 RCTs.
Limitations
- Prediction interval for HF hospitalization crossed 1.0, suggesting context-dependent effects.
- Equity-focused subgroup data were sparse; potential publication bias and inconsistency noted.
Future Directions: Prospective implementation trials comparing program designs, cost-effectiveness in diverse health systems, and equity-focused analyses (rurality, digital access) to maximize real-world benefit.
Whether the cumulative evidence for remote patient monitoring (RPM) in heart failure (HF) is robust to sequential monitoring, and whether trials report geographic access modifiers, remains uncertain. We conducted a systematic review, meta-analysis, and trial sequential analysis (TSA) of 65 randomized controlled trials (RCTs) (59 poolable; approximately 23,000 participants) identified through a search of PubMed/MEDLINE, Cochrane CENTRAL, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP) from inception through February 15, 2026, encompassing structured telephone support (STS) (15 trials), non-invasive telemonitoring (TM) (33 trials), and invasive hemodynamic monitoring (11 trials). Random-effects meta-analysis used restricted maximum likelihood (REML) with the Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment, and certainty of evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework. RPM significantly reduced all-cause mortality (ACM) (risk ratio (RR): 0.911, 95% confidence interval (CI): 0.842-0.985; P=0.021; I²=0%; k=41; number needed to treat (NNT) 104 per year; prediction interval: 0.840-0.988), and trial sequential analysis suggested that the accrued evidence exceeded the required information size under a 15% relative risk reduction assumption, supporting a stable mortality signal. HF hospitalization was reduced (RR: 0.781, 95% CI: 0.710-0.859; P<0.001; k=39; number needed to treat 18 per year), although the prediction interval crossed 1.0 (0.586-1.040), indicating that in some clinical settings, the effect may be attenuated. All-cause hospitalization was not significantly reduced (RR: 0.959, 95% CI: 0.892-1.031; k=28). No statistically significant interaction by RPM modality was detected for any primary outcome (all-cause mortality P-interaction=0.80; HF hospitalization P-interaction=0.14). GRADE certainty was moderate for all-cause mortality and low for HF hospitalization, downgraded primarily for suspected publication bias and inconsistency. A descriptive geographic access analysis revealed that only 2 of 59 poolable trials reported formal rural-versus-urban subgroup analyses, precluding firm conclusions about whether RPM differentially benefits geographically underserved populations. Within these limitations, remote patient monitoring appears to reduce all-cause mortality and HF hospitalization compared with usual care across diverse modalities, while signaling persistent gaps in heterogeneity reporting and equity-focused subgroup data.